

# Brent N Reed

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4247304/publications.pdf>

Version: 2024-02-01

64  
papers

931  
citations

471509

17  
h-index

501196

28  
g-index

65  
all docs

65  
docs citations

65  
times ranked

1469  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving and Expanding Research on Burnout and Stress in the Academy. American Journal of Pharmaceutical Education, 2023, 87, ajpe8907.	2.1	5
2	How Resilience and Wellness Behaviors Affected Burnout and Academic Performance of First-Year Pharmacy Students During COVID-19. American Journal of Pharmaceutical Education, 2023, 87, ajpe9022.	2.1	4
3	Situational judgment tests: An introduction for clinician educators. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 67-74.	1.0	6
4	Candidate reactions to a postgraduate year 1 pharmacy residency supplemental application. American Journal of Health-System Pharmacy, 2022, , .	1.0	2
5	Continuation Versus Interruption of Renin-Angiotensin System Inhibitors in Acute Decompensated Heart Failure: A Brief Report. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842211001.	2.0	0
6	Selection by design: Using job analysis to guide the selection of postgraduate pharmacy residents. American Journal of Health-System Pharmacy, 2022, 79, 1570-1579.	1.0	1
7	Association of lower urinary tract symptoms and diuretic adherence. LUTS: Lower Urinary Tract Symptoms, 2022, 14, 366-372.	1.3	1
8	Novel Use of Tamoxifen to Reduce Recurrent Gastrointestinal Bleeding in Patients with Left Ventricular Assist Devices. Journal of Cardiovascular Translational Research, 2021, 14, 484-491.	2.4	3
9	Comparing Diuresis Patterns in Hospitalized Patients With Heart Failure With Reduced Versus Preserved Ejection Fraction: A Retrospective Analysis. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 165-172.	2.0	2
10	Management of noncardiovascular comorbidities in patients with heart failure with reduced ejection fraction. Pharmacotherapy, 2021, 41, 537-545.	2.6	4
11	Rethinking letters of reference: Narrowing the gap between evidence and practice. American Journal of Health-System Pharmacy, 2021, , .	1.0	2
12	Clinical Outcomes of Perioperative Desensitization in Heart Transplant Recipients. Transplantation Direct, 2021, 7, e658.	1.6	4
13	The Impact of Two Longitudinal Professionalism Courses on Student Pharmacists's™ Empathy. American Journal of Pharmaceutical Education, 2021, 85, 8083.	2.1	4
14	Personality: A potentially untapped resource in the selection of postgraduate pharmacy residents. American Journal of Health-System Pharmacy, 2021, , .	1.0	1
15	Surveying the selection landscape: A systematic review of processes for selecting postgraduate year 1 pharmacy residents and key implications. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 245-256.	1.0	3
16	Addressing burnout with a work design approach. American Journal of Health-System Pharmacy, 2020, 77, 76-77.	1.0	1
17	Burnout among clinical pharmacists: Causes, interventions, and a call to action. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 832-842.	1.0	19
18	Feeling the burn? A systematic review of burnout in pharmacists. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 663-675.	1.0	56

#	ARTICLE	IF	CITATIONS
19	An aspirin a day? Clinical utility of aspirin therapy for the primary prevention of cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 561-573.	1.5	2
20	Clinical Pharmacologyâ€Driven Translational Research to Optimize Bedside Therapeutics of Sotalol Therapy. <i>Clinical and Translational Science</i> , 2019, 12, 648-656.	3.1	4
21	Alemtuzumab Induction Versus Conventional Immunosuppression in Heart Transplant Recipients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 435-441.	2.0	8
22	To tweet or not to tweet? A primer on social media for pharmacists. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 554-562.	1.0	8
23	Survey of Anticoagulation Practices with the Impella Percutaneous Ventricular Assist Device at High-Volume Centers. <i>Journal of Interventional Cardiology</i> , 2019, 2019, 1-6.	1.2	30
24	Continuation of Newly Initiated Midodrine Therapy. <i>Critical Care Medicine</i> , 2019, 47, e845.	0.9	1
25	Effect of Advanced Pharmacy Practice Experience Grading Scheme on Residency Match Rates. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 6735.	2.1	9
26	A Systematic Review of Leadership Definitions, Competencies, and Assessment Methods in Pharmacy Education. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 7520.	2.1	43
27	Diuretic Strategies and Renal Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 1049-1050.	4.1	0
28	Antithromboembolic Strategies for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 441-455.	2.2	0
29	No filter: A characterization of #pharmacist posts on Instagram. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 318-325.	1.5	5
30	Use of an argatroban-based purge solution in a percutaneous ventricular assist device. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, e163-e169.	1.0	30
31	Lessons in Bridge-Building: A Multidisciplinary Approach to Heart Failure Care. <i>Journal of Cardiac Failure</i> , 2017, 23, 574-575.	1.7	4
32	Diuretic Resistance in Acute Decompensated Heart Failure. <i>Critical Care Nursing Quarterly</i> , 2017, 40, 363-373.	0.8	9
33	Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support. <i>Pharmacotherapy</i> , 2017, 37, 1272-1283.	2.6	26
34	Observation of Patients Transitioned to an Oral Loop Diuretic Before Discharge and Risk of Readmission for Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 746-752.	1.7	10
35	Diltiazem versus metoprolol for rate control in atrial fibrillation with rapid ventricular response in the emergency department. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 2068-2076.	1.0	23
36	From Pilot to Practice: A Trainee-Integrated Pharmacy Practice Model in Cardiology. <i>North Carolina Medical Journal</i> , 2016, 77, 45-51.	0.2	5

#	ARTICLE	IF	CITATIONS
37	Safe and Effective Use of Pharmacologic and Device Therapy for Peripartum Cardiomyopathy. <i>Pharmacotherapy</i> , 2016, 36, 955-970.	2.6	8
38	Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance. <i>Pharmacotherapy</i> , 2016, 36, 852-860.	2.6	25
39	Beliefs and behaviors of professionally engaged pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2016, 56, 405-411.	1.5	9
40	Interactive Web-based regional journal club for postgraduate year 2 pharmacy residents in cardiology. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1300-1300.	1.0	1
41	Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e468-e495.	1.6	203
42	The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action. <i>American Heart Journal</i> , 2016, 175, 130-141.	2.7	36
43	Safety of Nonsteroidal Antiinflammatory Drugs in Patients with Cardiovascular Disease. <i>Pharmacotherapy</i> , 2015, 35, 520-535.	2.6	39
44	Medication Management of Cardiac Allograft Vasculopathy After Heart Transplantation. <i>Pharmacotherapy</i> , 2015, 35, 489-501.	2.6	20
45	Effects of an Accelerated Intravenous Iron Regimen in Hospitalized Patients With Advanced Heart Failure and Iron Deficiency. <i>Pharmacotherapy</i> , 2015, 35, 64-71.	2.6	20
46	Implementation and evaluation of a <i>CYP2C19</i> genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. <i>Pharmacogenomics</i> , 2015, 16, 303-313.	1.3	32
47	Impact of Video Technology on Efficiency of Pharmacist-Provided Anticoagulation Counseling and Patient Comprehension. <i>Annals of Pharmacotherapy</i> , 2015, 49, 631-638.	1.9	20
48	Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?. <i>Current Cardiology Reviews</i> , 2014, 11, 18-22.	1.5	12
49	Stage A: Can Heart Failure Be Prevented?. <i>Current Cardiology Reviews</i> , 2014, 11, 4-9.	1.5	4
50	Putting Class IIb Recommendations to the Test. <i>Critical Pathways in Cardiology</i> , 2014, 13, 78-81.	0.5	2
51	Acute Decompensated Heart Failure: Evolving Literature and Implications for Future Practice. <i>Pharmacotherapy</i> , 2014, 34, 373-388.	2.6	3
52	Time and Technology Will Tell. <i>Heart Failure Clinics</i> , 2014, 10, 543-557.	2.1	15
53	Polypharmacy in Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 577-590.	2.1	11
54	Distinguishing Anemia and Iron Deficiency of Heart Failure: Signal for Severity of Disease or Unmet Therapeutic Need?. <i>Pharmacotherapy</i> , 2014, 34, 719-732.	2.6	13

#	ARTICLE	IF	CITATIONS
55	A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF). <i>Current Cardiology Reviews</i> , 2014, 11, 23-32.	1.5	20
56	Clinical Update on the Management of Atrial Fibrillation. <i>Pharmacotherapy</i> , 2013, 33, 422-446.	2.6	15
57	Comparison of intravenous and oral magnesium replacement in hospitalized patients with cardiovascular disease. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1212-1217.	1.0	13
58	Key Articles and Guidelines in the Management of Pulmonary Arterial Hypertension: 2011 Update. <i>Pharmacotherapy</i> , 2012, 32, e134-e169.	2.6	2
59	Fluconazole Prophylaxis in High-Risk Neonates. <i>Annals of Pharmacotherapy</i> , 2010, 44, 178-184.	1.9	18
60	Health care reform and the role of the pharmacist. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2009, 49, 356-362.	1.5	2
61	Pharmacy Practice around the World. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2009, 49, 4-10.	1.5	5
62	Building a Sustainable System of Leadership Development for Pharmacy: Report of the 2008-09 Argus Commission. <i>American Journal of Pharmaceutical Education</i> , 2009, 73, S05.	2.1	42
63	Building the business model for medication therapy management services. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2008, 48, 16-22.	1.5	6
64	Continuous quality improvement in all phases of practice mandatory for preventing medication errors. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2007, 47, 443-451.	1.5	0